Landscapes / Targets
VEGFR2
18 drugs act on VEGFR2, in 50 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs18
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Kinase inhibitor |
Pfizer · Public PFE |
Approved | 31 Dec 2026Phase 3 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 31 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Advanced Malignancies, NSCLC and 16 more | ||||
| Open drug page | |||||
VEGFR2 antibody |
Eli Lilly · Public LLY |
Approved | May 2027Phase 2 trial completes | ||
| Next date | May 2027 · Phase 2 trial completes | ||||
| Also tested for | Metastatic Non-Small Cell Lung Cancer, Biliary Tract Cancer and 5 more | ||||
| Open drug page | |||||
— |
Hengrui · Public 600276.SS |
Approved in China | Jul 2027Phase 2 trial completes | ||
| Next date | Jul 2027 · Phase 2 trial completes | ||||
| Also tested for | Gastric Cancer, Hepatocellular Carcinoma (HCC) and 1 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | 1 Feb 2028Phase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 1 Feb 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL), Acute Myeloid Leukemia and 8 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | 27 Apr 2028Phase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 27 Apr 2028 · Phase 2 trial completes | ||||
| Also tested for | Solid Malignant Tumors | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Approved in China | 31 May 2028Phase 2/3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 31 May 2028 · Phase 2/3 trial completes | ||||
| Also tested for | Metastatic Pancreatic Cancer | ||||
| Open drug page | |||||
Monoclonal antibody |
Akeso · Public 9926.HK |
Phase 3 | Nov 2026soonPhase 3 trial completes | ||
| How it works | An antibody | ||||
| Next date | Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, Gastric and Gastroesophageal Junction Adenocarcinoma | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Phase 3 | 15 Dec 2026soonPhase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 15 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Colorectal Cancer, Renal Cell Carcinoma and 32 more | ||||
| Open drug page | |||||
— |
Phase 3 | 30 Dec 2026Phase 3 trial completes | |||
| Next date | 30 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Esophageal Squamous Cell Carcinoma, Ewing Sarcoma and 1 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Phase 3 | 30 Jan 2027Phase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 30 Jan 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma and 3 more | ||||
| Open drug page | |||||
— |
Phase 3 | Oct 2027Phase 3 trial completes | |||
| Next date | Oct 2027 · Phase 3 trial completes | ||||
| Also tested for | Wet Age Related Macular Degeneration, wAMD and 3 more | ||||
| Open drug page | |||||
— |
Phase 2 | Dec 2026Phase 1/2 trial completes | |||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Renal Cell Carcinoma, Differentiated Thyroid Carcinoma and 1 more | ||||
| Open drug page | |||||
PD-1/VEGFR2 bifunctional antibody |
Ottimo Pharma · Private |
Phase 1/2 | Dec 2028Phase 1/2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | Dec 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumors | ||||
| Open drug page | |||||
— |
Phase 1/2 | — | |||
| Also tested for | Solid Tumor | ||||
| Open drug page | |||||
— |
AstraZeneca · Public AZN |
Phase 2 | — | ||
| Also tested for | Solid Tumors, Non-Small Cell Lung Cancer | ||||
| Open drug page | |||||
— |
Phase 1 | 30 Dec 2026Phase 1 trial completes | |||
| Next date | 30 Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | Wet Age Related Macular Degeneration, Neovascular (Wet) Age-Related Macular Degeneration | ||||
| Open drug page | |||||
— |
Phase 1 | 7 Mar 2027Phase 1 trial completes | |||
| Next date | 7 Mar 2027 · Phase 1 trial completes | ||||
| Also tested for | Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma and 1 more | ||||
| Open drug page | |||||
— |
Phase 1 | Jun 2027Phase 1 trial completes | |||
| Next date | Jun 2027 · Phase 1 trial completes | ||||
| Also tested for | Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma and 7 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 18 of 18 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026